Navigation Links
New Peer-Reviewed Study Shows Mixed Results in ACO Medication Readiness To Achieve Quality, Cost Goals

WASHINGTON, Jan. 6, 2014 /PRNewswire-USNewswire/ -- As Accountable Care Organizations (ACOs) gain traction among both private and public payers, so do expectations that these networks of health care providers will improve the quality of patient care and reduce overall costs. However, new research shows that ACOs have not yet developed the capabilities they need to leverage optimal medication use to achieve those goals.   

The research, conducted in partnership among the National Pharmaceutical Council (NPC), the American Medical Group Association (AMGA) and Premier, Inc. (NASDAQ: PINC), appears in the January 2014 issue of the Journal of Managed Care Pharmacy.

"We've long known that optimal use of medications can be an effective tool in meeting the goals of managing costs and improving quality. We set out to determine whether ACOs are poised to maximize the value of medications to achieve those goals," said NPC Chief Science Officer Robert W. Dubois, MD, PhD, one of the article's authors. "What we found was that ACOs have not yet achieved this integral and critical component of care."

The research team developed an assessment tool, using the National Survey of Accountable Care Organizations as a basis, and received survey responses from 46 ACOs representing a variety of physicians, hospitals, providers and health plans. 

Study authors found that ACOs reported high readiness in some areas, but have room for improvement in others. Research showed that the most positive indicators included the ability of ACOs to: 

  • Transmit prescriptions electronically (70 percent have high readiness in this area)
  • Integrate medical and pharmacy data into a single database (54 percent)
  • Offer formularies that encourage generic use when appropriate (50 percent)

However, survey responses show ACOs are just beginning to address several key capabilities, including the ability to:

  • Notify a physician when a prescription has been filled (9 percent)
  • Have protocols in place to avoid medication duplication and polypharmacy (17 percent)
  • Have quality metrics in place for a broad diversity of conditions (22 percent)
  • Quantify the cost offsets of medication use and demonstrate the value of appropriate medication use (7 percent have high readiness in this area)

"Just as physicians need to consider when medications are appropriate for individual  patients, ACOs are under the same imperative to put processes into place that will allow them to use medications to maximize the benefit for all of their patients," said Donald W. Fisher, PhD, CAE, AMGA president and CEO.

The study is part of a broader project supported by NPC, AMGA and Premier to understand the role of pharmaceuticals in helping ACOs achieve their financial and quality goals. In the project's foundational stage, the partners, working in conjunction with a group of ACOs, developed a framework for considering the costs and benefits of medications in various conditions. The results of that effort were published as a web exclusive in the July 2012 issue of the American Journal of Managed Care. Following the readiness assessment and gap identification captured in this current study, additional phases will include the development of practical tools that will help ACOs fill those gaps. To advance the discussion, NPC, AMGA, Premier and the ACO group have begun documenting case studies that will provide ACOs with examples of how certain medication issues have been successfully addressed by ACOs or relevant organizations.

"In general, ACOs have made great strides as models to deliver high-quality, cost-effective care and improve population health. For ACOs to realize their full potential, the various moving parts of healthcare delivery—primary care, hospital care, home care, chronic condition management and medication use—will have to be used in concert," said Marv Feldman, RPh, MS, Premier managing principal of pharmacy consulting and senior director of medication management and a contributing author. "This collaboration is making important progress in understanding the unmet needs and resources needed for ACOs to achieve their goals."

NPC, AMGA and Premier will participate in a webinar on January 14, 2014, at 1 p.m. to discuss their research. Registration is available online at and there is no charge to attend. 

About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit and follow NPC on Twitter @npcnow.

About the American Medical Group Association
The American Medical Group Association (AMGA) is a 501(c)(6) trade association representing medical groups, health systems, and other organized systems of care, including some of the nation's largest, most prestigious integrated delivery systems. AMGA is a leading voice in advocating for efficient, team-based, and accountable care. AMGA members encompass all models of organized systems of care in the healthcare industry, including: physician-owned, independent group practices, integrated delivery systems, hospital-affiliated medical groups, independent practice associations (IPAs), academic and faculty practices, accountable care organizations, and high-performing health systems. More than 130,000 physicians practice in AMGA member organizations, providing healthcare services for 120 million patients (approximately one in three Americans). Headquartered in Alexandria, Va., AMGA is the strategic partner for these organizations, providing a comprehensive package of benefits, including political advocacy, educational and networking programs, publications, benchmarking data services, and financial and operations assistance.

About Premier, Inc.
Premier, Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 2,900 U.S. hospitals and nearly 100,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier's news and investor sites on; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram, Foursquare and Premier's blog for more information about the company.

SOURCE National Pharmaceutical Council
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Absorption Systems Scientists Publish Peer-reviewed Paper on a Key Drug Transporter
2. Sigma-Aldrich Launches Novel Search Engine for Peer-Reviewed Literature, Biological Pathway Data and Technology Queries
3. Star Scientific Reports Publication of First Peer-Reviewed Article on the Effects of Anatabine in an Animal Model of Multiple Sclerosis
4. Scioderm Initiates Phase 2B Study of SD-101, A Novel Topical Therapy, for Patients with Epidermolysis Bullosa
5. Luoxis Establishes Study Collaborations with Two Research Centers in Oxidative Stress
6. ideaPoint, Inc. Announces Launch of Multi-Sponsor Portal Providing Researchers Opportunity to Request Access to Clinical Data from Five Global Study Sponsors
7. Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes
8. PCMA: New Study Confirms $217 Billion in Savings from Generic Medications in 2012
9. Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
10. ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study
11. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
Post Your Comments:
(Date:11/30/2015)... HANOVER, N.J. , Nov. 30, 2015  Novartis ... portfolio at the 57 th American Society of ... leukemias, lymphomas and myelomas as well as supportive care, ... in addition to personalized cell therapies. The ASH Annual ... Orlando, Florida . Novartis Oncology . ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
(Date:11/30/2015)... 2015 Elbit Imaging Ltd. (TASE, ... today that it was informed by InSightec Ltd. ("InSightec"), that ... has approved its Exablate Neuro system to treat movement, ... --> Insightec,s Exablate Neuro platform is transforming ... two technologies: Focused Ultrasound, which is used to lesion ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb ... the leading plastic surgery practices in Florida, is proud to announce that Dr. ... surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon is ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational New Drug ... so important to this key industry segment, Regis Technologies has decided to sponsor and ... 4th at 11am EST. , Federal law does not allow new drugs to cross ...
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. ... Inc., a Healthcare IT consulting, development and support company. The purchase will expand ... available within DataTrade to extend the services currently provided by Healthjump. ...
(Date:11/30/2015)... ... November 30, 2015 , ... GKhair & Tibolli team members and artists were ... held on November 8th and 9th at the Puerto Rico Convention Center, San Juan ... beauticians and top of the line fashion journalists. The San Juan Beauty Show carries ...
(Date:11/30/2015)... ... 2015 , ... Innovaacom, a leading provider of medical education ... of educational needs for pharmacists worldwide. The poll of pharmacists in Europe, Asia, ... online and face-to-face education for pharmacists who are fast becoming the new “gatekeepers” ...
Breaking Medicine News(10 mins):